tradingkey.logo

Sol Gel Technologies Ltd

SLGL
65.270USD
-0.510-0.78%
收盤 02/09, 16:00美東報價延遲15分鐘
117.39M總市值
虧損本益比TTM

Sol Gel Technologies Ltd

65.270
-0.510-0.78%

關於 Sol Gel Technologies Ltd 公司

Sol-Gel Technologies Ltd is a clinical-stage dermatology company. The Company is focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The Company’s offers a range of products twins, sirs-t, and vered. The Company is designed its proprietary, silica-based microencapsulation technology platform to enhance the tolerability and stability of topical drugs while maintaining their efficacy. Topical drugs often struggle to balance achieving both high efficacy and high tolerability. Its technology platform entraps active ingredients in an inert, inorganic silica shell, which creates an unnoticeable barrier between the active ingredient and the skin.

Sol Gel Technologies Ltd簡介

公司代碼SLGL
公司名稱Sol Gel Technologies Ltd
上市日期Feb 01, 2018
CEO- -
員工數量34
證券類型Ordinary Share
年結日Feb 01
公司地址Golda Meir 7
城市NESS-ZIONA
上市交易所NASDAQ OMX - NASDAQ BASIC
國家Israel
郵編- -
電話97289313433
網址http://www.sol-gel.com
公司代碼SLGL
上市日期Feb 01, 2018
CEO- -

Sol Gel Technologies Ltd公司高管

名稱
名稱/職務
職務
持股
持股變動
Mr. Moshe (Mori) Arkin
Mr. Moshe (Mori) Arkin
Executive Chairman of the Board
Executive Chairman of the Board
143.26K
+105123.00%
Dr. Ofer Toledano, Ph.D.
Dr. Ofer Toledano, Ph.D.
Vice President - Research and Development
Vice President - Research and Development
--
--
Dr. Ofra Levy-Hacham, Ph.D.
Dr. Ofra Levy-Hacham, Ph.D.
Vice President - Clinical and Regulatory Affairs
Vice President - Clinical and Regulatory Affairs
--
--
Dr. Karine Neimann, Ph.D.
Dr. Karine Neimann, Ph.D.
Vice President - Projects and Planning, Chief Chemist
Vice President - Projects and Planning, Chief Chemist
--
--
Dr. Itzik Yosef, Ph.D.
Dr. Itzik Yosef, Ph.D.
Vice President - Operations
Vice President - Operations
--
--
Dr. Dubi (Dov) Zamir, Ph.D.
Dr. Dubi (Dov) Zamir, Ph.D.
Vice President - Special Projects
Vice President - Special Projects
--
--
Mr. Itai Arkin
Mr. Itai Arkin
Director
Director
--
--
Dr. Shmuel (Muli) Ben Zvi, Ph.D.
Dr. Shmuel (Muli) Ben Zvi, Ph.D.
Independent Director
Independent Director
--
--
Ms. Hani Lerman
Ms. Hani Lerman
Director
Director
--
--
Mr. Ran Gottfried
Mr. Ran Gottfried
Lead Independent Director
Lead Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Moshe (Mori) Arkin
Mr. Moshe (Mori) Arkin
Executive Chairman of the Board
Executive Chairman of the Board
143.26K
+105123.00%
Dr. Ofer Toledano, Ph.D.
Dr. Ofer Toledano, Ph.D.
Vice President - Research and Development
Vice President - Research and Development
--
--
Dr. Ofra Levy-Hacham, Ph.D.
Dr. Ofra Levy-Hacham, Ph.D.
Vice President - Clinical and Regulatory Affairs
Vice President - Clinical and Regulatory Affairs
--
--
Dr. Karine Neimann, Ph.D.
Dr. Karine Neimann, Ph.D.
Vice President - Projects and Planning, Chief Chemist
Vice President - Projects and Planning, Chief Chemist
--
--
Dr. Itzik Yosef, Ph.D.
Dr. Itzik Yosef, Ph.D.
Vice President - Operations
Vice President - Operations
--
--
Dr. Dubi (Dov) Zamir, Ph.D.
Dr. Dubi (Dov) Zamir, Ph.D.
Vice President - Special Projects
Vice President - Special Projects
--
--

收入明細

由於公司未披露,未能獲取相關數據
由於公司未披露,未能獲取相關數據
業務
地區
由於公司未披露,未能獲取相關數據

股東統計

更新時間: 2月6日 週五
更新時間: 2月6日 週五
持股股東
股東類型
持股股東
持股股東
佔比
M.Arkin Dermatology, Ltd.
64.86%
Opaleye Management Inc.
13.78%
Phoenix Investment and Finances Ltd
7.83%
Arkin (Moshe)
5.14%
Yelin Lapidot Provident Funds Management Ltd
0.64%
其他
7.75%
持股股東
持股股東
佔比
M.Arkin Dermatology, Ltd.
64.86%
Opaleye Management Inc.
13.78%
Phoenix Investment and Finances Ltd
7.83%
Arkin (Moshe)
5.14%
Yelin Lapidot Provident Funds Management Ltd
0.64%
其他
7.75%
股東類型
持股股東
佔比
Corporation
64.86%
Hedge Fund
13.78%
Investment Advisor
8.54%
Individual Investor
5.14%
Insurance Company
0.27%
Research Firm
0.16%
Investment Advisor/Hedge Fund
0.05%
其他
7.20%

機構持股

更新時間: 1月1日 週四
更新時間: 1月1日 週四
報告期間
機構數
持股數
持股佔比
持股變動
2025Q4
35
634.85K
22.79%
-440.31K
2025Q3
35
286.02K
10.27%
-480.14K
2025Q2
36
2.50M
89.88%
-104.83K
2025Q1
37
2.45M
84.60%
+78.00K
2024Q4
35
23.50M
84.37%
-314.30K
2024Q3
34
23.55M
84.52%
-115.49K
2024Q2
31
25.52M
91.61%
+1.51M
2024Q1
30
23.87M
85.67%
+1.61M
2023Q4
31
22.12M
83.66%
-222.95K
2023Q3
30
22.20M
83.99%
-4.35K
查看更多

股東持股明細

名稱
持股數
佔比
持股變動
變動比例
公告日期
M.Arkin Dermatology, Ltd.
1.81M
64.86%
--
--
Jun 11, 2025
Opaleye Management Inc.
383.58K
13.77%
+10.43K
+2.80%
Dec 17, 2025
Phoenix Investment and Finances Ltd
218.22K
7.83%
-28.80K
-11.66%
Sep 30, 2025
Arkin (Moshe)
143.26K
5.14%
+105.12K
+275.67%
Jun 11, 2025
Menora Mivtachim Insurance Ltd.
7.61K
0.27%
+7.61K
--
Sep 30, 2025
Morgan Stanley & Co. LLC
4.37K
0.16%
-970.00
-18.18%
Sep 30, 2025
Steward Partners Investment Advisory, LLC
316.00
0.01%
--
--
Sep 30, 2025
查看更多

持股ETF

更新時間: 12月2日 週二
更新時間: 12月2日 週二
機構名稱
佔比
Invesco Raymond James SB-1 Equity ETF
0%
Invesco Raymond James SB-1 Equity ETF
佔比0%

分紅派息

近5年累計派現 0.00 美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據

拆合股

公告日期
除權除息日
類型
比率
May 01, 2025
Merger
10→1
公告日期
除權除息日
類型
比率
May 01, 2025
Merger
10→1
KeyAI